Organization | Infectious Disease Research Institute

Infectious Disease Research Institute Report issue

Foundation Phase 1 Phase 2

Founded: Seattle WA United States (1993)

Organization Overview

First Clinical Trial

2004

NCT00111514

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Infectious Disease Research Institute (IDRI)

Active Ingredients

Drugs in Phase 2 Trials (6)

gla-se (6 trials)

id93 (3 trials)

leish-111f + mpl-se (5 trials)

leish-f2 (1 trial)

monophosphoryl lipid a (1 trial)

sodium stibogluconate (Pentostam) (1 trial)

Drugs in Phase 1 Trials (11)

3m-052-af (1 trial)

aluminum hydroxide (Gaviscon) (2 trials)

bg505 sosip.664 gp140 (1 trial)

cpg 1018 (1 trial)

gla-af (2 trials)

gla-lsq (1 trial)

inactivated influenza vaccine (1 trial)

influenza vlp vaccine (1 trial)

leish-f2 + mpl-se (1 trial)

leish-f3 (2 trials)

leish-f3 + sla-se (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

HIV Infections (Phase 1)

Influenza, Human (Phase 1)

Influenza in Birds (Phase 1)

Leishmaniasis (Phase 2)

Leishmaniasis, Cutaneous (Phase 2)

Leishmaniasis, Mucocutaneous (Phase 1)

Leishmaniasis, Visceral (Phase 1)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 15
# of Trial APIs: 17